Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Starbucks Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.76 (market cap $39.89B), while Starbucks Corp trades at $107.84 (market cap $120.82B). The key difference: Starbucks Corp is far larger — about 3× Alnylam Pharmaceuticals, Inc.'s market cap, and Starbucks Corp pays a 2.34% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SBUX | |
|---|---|---|
Market Cap | $39.89B | $120.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $106.82 |
52-Week Low | $278.09 | $78.46 |
Enterprise Value | $38.15B | $143.51B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Starbucks (SBUX) trades at $106.01, down 0.38% today, with a bullish technical signal and recent earnings beat in Q1 2026. The company's revenue grew to $37.18B in 2025, though net income margin compressed to 3.89%. Recent news highlights AI initiatives to cut software costs, while analyst consensus is split evenly between Buy and Hold ratings with a $107.67 price target.
Outlook remains mixed: AI cost savings and loyalty growth offer upside, but margin pressure and high P/E of 80.92 pose risks. Near-term performance hinges on Q2 2026 earnings versus the $0.65 EPS estimate and execution of operational efficiencies amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
